Mecasermin
FDA approved · RxRecombinant IGF-1 hormone
Also known as: Increlex, IGF-1, rhIGF-1
Strong, human-grade evidence
- Regulatory standing. FDA-approved prescription medicine
- Human trials. Backed by controlled human studies
- Registered human trials. 37 registered studies on ClinicalTrials.gov, most advanced Phase 3
- 1 cited source. Includes primary / regulatory sources
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Mecasermin is a lab-made version of human insulin-like growth factor 1 (IGF-1), a hormone that normally mediates many of the growth effects of growth hormone. It binds the IGF-1 receptor to support bone and tissue growth, and it also has insulin-like effects on blood sugar.
What the evidence shows
Mecasermin (Increlex) is FDA approved for growth failure in children with severe primary IGF-1 deficiency, supported by 37 registered human trials reaching Phase 3. Uses outside that approved indication, such as for muscle building, anti-aging, or athletic performance, are not established in humans.
Key facts
Registered human trials
Live from ClinicalTrials.gov, refreshed daily.
Long-Term Treatment With rhIGF-1 in GHIS
Metabolic Effects of GH and IGF-I in Growth Hormone Deficient(GHD) and Diabetes and Impaired Glucose Tolerance(IGT)
Treatment of Rett Syndrome With Recombinant Human IGF-1
IGF-1 and Bone Loss in Women With Anorexia Nervosa
Published literature
Live from Europe PMC. This is how much has been published, not how much is proven in humans.
Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome.
Placebo-controlled crossover assessment of mecasermin for the treatment of Rett syndrome.
The insulin-like growth factor I system: physiological and pathophysiological implication in cardiovascular diseases associated with metabolic syndrome.
Insulinlike growth factor (IGF)-1 administration ameliorates disease manifestations in a mouse model of spinal and bulbar muscular atrophy.
Sources
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.